Long‐Term Follow‐Up of Patients With Mitochondrial Carbonic Anhydrase VA Deficiency. A Case Report and Literature Review Authors: Shaymaa Shurrab, Amira Mobarak, Gabriella Horvath, Sylvia Stocker‐Ipsiroglu, Clara van Karnebeek, Ramona Salvarinova‐Zivkovic Published: 2026 ABSTRACT ABSTRACTMitochondrial carbonic anhydrase VA (CA‐VA) deficiency is a rare inherited metabolic disorder caused by biallelic variants of the CA5A gene. It presents with hyperammonemia, lactic acidosis, and ketonuria, with or without hypoglycemia. We report the long‐term follow‐up of the first two reported cases of CA‐VA deficiency: a 16‐year‐old female (case 1) and her 14‐year‐old brother (case 2), both of whom presented with neonatal hyperammonemic encephalopathy, hypoglycemia, elevated lactate, ketonuria, and compensated metabolic acidosis. The diagnosis was made in both cases through the TIDEX study, which identified a homozygous pathogenic variant in the CA5A gene (c.697T>C, (p.Ser233Pro)). The clinical course of the index patient revealed three additional metabolic decompensation episodes (MDEs) triggered by intercurrent illnesses, with the last episode occurring at 8 years of age, highlighting the unusual timing of her MDEs compared to previously reported cases. Case 2 remained metabolically stable without any additional MDEs. These episodes were successfully treated with parenteral dextrose, a single dose of enteral carglumic acid, and occasionally parenteral lipids. Management of intercurrent illness included a sick‐day formula high in carbohydrates and fats. Currently, both cases show normal growth, development, and neurological outcomes, suggesting a favorable prognosis, and in keeping with previously reported cases. Early diagnosis of CA‐VA deficiency allows prompt treatment and prevents severe complications. With proper management, long‐term outcomes are favorable, although severe and fatal outcomes have been reported. The impact on longevity needs to be assessed over longer durations. The development of consensus management for CA‐VA deficiency is warranted.Keywords: CA‐VA deficiency, encephalopathy, hyperammonemia, ketoacidosis, lactic acidosis, long‐term outcomes Introduction Carbonic anhydrase VA (CA‐VA) is a member of the carbonic anhydrase family. Encoded by the CA5A gene (OMIM # 114761) and predominantly expressed in the hepatic, renal, and skeletal muscles' mitochondria, CA‐VA catalyzes the intramitochondrial reversible hydration of carbon dioxide, producing bicarbonate (HCO3 −) that is utilized in subsequent physiological processes, including ureagenesis, gluconeogenesis, and lipogenesis [1, 2]. As mitochondria are impermeable to HCO3 −, its intramitochondrial production is essential for the function of 4 mitochondrial bicarbonate‐dependent enzymes (Figure 1): carbamoyl phosphate synthetase 1 (CPS1), pyruvate carboxylase (PC), propionyl CoA carboxylase (PCC), and 3‐methylcrotonyl CoA carboxylase (3MCC). The metabolic pathways affected by CA‐VA deficiency: CA‐VA (bidirectional bolded black arrow) is responsible for the intramitochondrial production of bicarbonate (HCO3 − highlighted in red font and red‐colored boxes). There are four mitochondrial enzymes (enzymes are in blue color & reactions presented in red bolded arrows) that require HCO3 −: Carbamoyl phosphate synthetase 1 (CPS1), pyruvate carboxylase (PC), propionyl CoA carboxylase (PCC), and 3‐methylcrotonyl CoA carboxylase (3MCC). Created in https://BioRender.com. In the past decade, CA‐VA deficiency (OMIM # 615751) has been identified as a treatable cause of neonatal and infantile hyperammonemic encephalopathy. However, data on long‐term outcomes remain limited. In this report, we provide long‐term follow‐up for two previously reported cases [3, 4] and a systematic review of all 69 cases published to date. Case Report Initial Presentation Case 1 (case II‐1, Figure 2) and her brother, case 2 (case II‐2, Figure 2), were born at term following an uncomplicated pregnancy and delivery to non‐consanguineous, healthy parents of Caucasian ancestry [3]. Both cases presented on the second and first days of life, respectively, with neonatal hyperammonemic encephalopathy, hypoglycemia, elevated lactate, and a complex acid–base disturbance suggestive of metabolic acidosis with respiratory alkalosis (Table 1). Other investigations, including liver transaminases, coagulation profile, kidney function tests, and urate levels, were within the normal range. Family pedigree of cases 1 and 2: The arrow indicates the index case. The filled figures (cases II‐1 and II‐2) indicate affected individuals with CA‐VA deficiency (CA5A −/−, homozygous for c.697T>C). The half‐filled figures (cases I‐1, I‐2, and II‐3) indicate carriers of the CA5A c.697T>C (CA5A −/+). Created in https://BioRender.com. TABLE 1Summary of the investigations carried out in cases 1 and 2.InvestigationsCase 1Case 2Routine investigations a Blood glucose: 2.2 mmol/L Sodium: 154 mmol/L (135–145) Lactate: 9.8 mmol/L (0.5–2.2) Ammonia: 438 μmol/L (< 45) Beta hydroxybutyrate: 10 μmol/L (< 0.3) Venous blood gas: pH: 7.48, pCO2: 10.8 mmHg, and HCO3 −: 10.4 mEq/L Blood glucose: 2.9 mmol/L Sodium: 150 mmol/L (135–145) Lactate: 8.8 mmol/L (0.5–2.2) Lactate to pyruvate ratio: 158 (10–20.7) Ammonia: 238 μmol/L (< 45) Venous blood gas: pH: 7.54, pCO2: 22, HCO3 −: 23 mEq/L Provincial newborn screening a Negative for all screened disorders.Negative for all screened disorders.Plasma amino acids (μmol/L) a Elevated glutamine: 1044 (243–822) Elevated proline: 475 (144–329) Elevated alanine: 811 (132–455) Low ornithine: 28 (38–207) Low citrulline: 5 (8–47) Low arginine: 17 (32–142) Elevated glutamine 1237 (243–822) Elevated alanine: 609 (132–455) Arginine (measured following IV arginine administration): 572 (17–119) Normal citrulline: 18 (3–36) Normal ornithine: 82 (27–207) Acylcarnitine profile (μmol/L) a UnremarkableUnremarkableUrine organic acids (mmol/mol creatinine) a Substantial elevation of lactate in urine, marked ketonuria, and mild elevation in branched‐chain keto and hydroxy acids Orotic acid was not detectable Moderate lactic aciduria and ketonuria, significant increase in pyruvic acid, mild elevation of Krebs cycle intermediates and tyrosine metabolites, and dicarboxylic aciduria Orotic acid and uracil were within the reference range Urine amino acids a UnremarkableUnremarkableBiotinidase activityUnremarkableUnremarkablePyruvate carboxylase activity in fibroblastsNot performedUnremarkableRespiratory chain complexes I‐V blue native electrophoresisNot performedUnremarkableBrain (MRI/MRS) a Unremarkable Petechial focus of diffusion restriction adjacent to the posterior aspect of the trigone of the right lateral ventricle in keeping with a small focus of nonspecific white matter injury b MRS: normal EEG a UnremarkableNot performedCardiac evaluation a Echocardiography: Left ventricular hypertrophy c Echocardiography: Localized area of septal thickness of unknown significance d ECG: Normal Sinus Rhythm Abdominal ultrasoundNo abnormalities in the liver or kidneysNo abnormalities in the liver or kidneysChromosomal microarray a Normal femaleNormal male NAGS and CPS1 gene sequencing and deletion/duplication analysis.UnremarkableNot performed TMEM70 and PC gene sequencingNot performedUnremarkableWESHomozygous for (NM_001739.1: c.697T>C, NP_001730.1: p.Ser233Pro) in the CA5A gene, ACMG classification: pathogenicHomozygous for (NM_001739.1: c.697T>C, NP_001730.1: p.Ser233Pro) in the CA5A gene, ACMG classification: pathogenic Note: Institution reference ranges are indicated between brackets.Abbreviation: ACMG, American College of Medical Genetics. a Tests obtained during the initial presentation in the neonatal period. b Repeat MRI at the age of 11 years was normal. c Follow‐up echocardiography at 2, 3, 10 years of age and then annually was normal. d Findings normalized on repeat studies annually. Summary of the investigations carried out in cases 1 and 2. Blood glucose: 2.2 mmol/L Sodium: 154 mmol/L (135–145) Lactate: 9.8 mmol/L (0.5–2.2) Ammonia: 438 μmol/L (< 45) Beta hydroxybutyrate: 10 μmol/L (< 0.3) Venous blood gas: pH: 7.48, pCO2: 10.8 mmHg, and HCO3 −: 10.4 mEq/L Blood glucose: 2.9 mmol/L Sodium: 150 mmol/L (135–145) Lactate: 8.8 mmol/L (0.5–2.2) Lactate to pyruvate ratio: 158 (10–20.7) Ammonia: 238 μmol/L (< 45) Venous blood gas: pH: 7.54, pCO2: 22, HCO3 −: 23 mEq/L Elevated glutamine: 1044 (243–822) Elevated proline: 475 (144–329) Elevated alanine: 811 (132–455) Low ornithine: 28 (38–207) Low citrulline: 5 (8–47) Low arginine: 17 (32–142) Elevated glutamine 1237 (243–822) Elevated alanine: 609 (132–455) Arginine (measured following IV arginine administration): 572 (17–119) Normal citrulline: 18 (3–36) Normal ornithine: 82 (27–207) Substantial elevation of lactate in urine, marked ketonuria, and mild elevation in branched‐chain keto and hydroxy acids Orotic acid was not detectable Moderate lactic aciduria and ketonuria, significant increase in pyruvic acid, mild elevation of Krebs cycle intermediates and tyrosine metabolites, and dicarboxylic aciduria Orotic acid and uracil were within the reference range Petechial focus of diffusion restriction adjacent to the posterior aspect of the trigone of the right lateral ventricle in keeping with a small focus of nonspecific white matter injury b MRS: normal Echocardiography: Localized area of septal thickness of unknown significance d ECG: Normal Sinus Rhythm Note: Institution reference ranges are indicated between brackets. Abbreviation: ACMG, American College of Medical Genetics. Tests obtained during the initial presentation in the neonatal period. Repeat MRI at the age of 11 years was normal. Follow‐up echocardiography at 2, 3, 10 years of age and then annually was normal. Findings normalized on repeat studies annually. Following their initial presentation, both cases were transferred to a tertiary center and were admitted to the pediatric intensive care unit (PICU). Management included intravenous (IV) 10% dextrose at 150% maintenance, bicarbonate infusion to correct metabolic acidosis, and enteral carglumic acid (Carbaglu; 100 mg/kg/day) for hyperammonemia. Their symptoms resolved, and their biochemical profiles normalized upon initiation of treatment. In case 1, protein intake was restricted but increased gradually as ammonia levels normalized. Due to concerns regarding primary mitochondrial disorders, coenzyme Q10 (CoQ10; 50 mg/day), l‐carnitine (100 mg/kg/day), and vitamin C (60 mg/day) were initiated. Results The results of these investigations are summarized in Table 1. Both cases underwent comprehensive metabolic workups, including plasma amino acid (PAA), plasma acylcarnitine profile (ACP), urine organic acids (UOA), urine amino acids (UAA), and biotinidase activity. Additionally, PC activity in fibroblasts and respiratory chain complexes I–V blue native electrophoresis were performed in case 2. Both cases underwent brain magnetic resonance imaging and spectroscopy (MRI/MRS), echocardiography, and abdominal ultrasound, while electroencephalography (EEG) was obtained only in case 1. Whole Exome Sequencing (WES) was conducted through the Treatable Intellectual Disability Endeavor (TIDEX) study, and a homozygous variant in CA5A gene (NM_001739.1: c.697T>C, NP_001730.1: p.Ser233Pro) was identified and confirmed by Sanger sequencing. The variant was subsequently confirmed as pathogenic, thereby establishing the diagnosis of CA‐VA deficiency in cases 1 and 2 at ages 6 years 3 months and 4 years 3 months, respectively [3]. Further Metabolic Decompensation Episodes (MDEs) Case 1 experienced three additional MDEs at ages 2 years 6 months, 3 years 6 months, and 8 years, all triggered by febrile illnesses. During these episodes, she presented with altered levels of consciousness, vomiting, hypoglycemia, massive ketonuria, elevated lactate (9.1, 8.7, and 7.3 mmol/L, respectively), hyperammonemia (peaking at 780, 420, and 266 μmol/L, respectively), and metabolic acidosis. HyperCKemia was reported during all subsequent MDEs (CK: 1414, 514, and 342 U/L, respectively; reference range: 50–305). She was treated with protein restriction, IV dextrose, IV lipids (1–2 g/kg/day), and a single dose of carglumic acid (100 mg/kg/day). Given her metabolic stability, l‐carnitine (50 mg/kg/day) was discontinued at the age of 11 years. Case 2 remained stable without additional MDEs. Ultimately, his l‐carnitine was stopped at 8 years of age. Outside the MDEs seen in case 1, both cases experienced febrile illnesses that were successfully managed with a sick‐day formula to provide high‐calorie intake with increased lipids and carbohydrates (each 100 mL of the formula provides: 0 g of protein, 18.3 g of carbohydrate, 3.8 g of fat and 107 kcal, administered to provide 1.3 mL/kg/h and glucose infusion rate (GIR) of 4 mg/kg/min) and avoidance of fasting. Both cases continued normal/high protein intake (~4 g/kg/day), CoQ10 (150 mg/day) and vitamin C (60 mg/day) supplements, while a zinc supplement (3 mg/day) was provided intermittently during times of confirmed nutritional deficiency. The annual surveillance, including ophthalmology, cardiac, liver and renal, remained unremarkable. Development, Growth, and Neurological Outcome At age 4 years 3 months, case 1 underwent a comprehensive developmental and behavioral assessment. Her cognitive abilities, basic concept knowledge, single‐word expressive and receptive vocabulary, and visual‐motor integration were at or above average compared to her peers of the same age. Her fine motor coordination was average, with occasional fatigue‐related difficulties. However, she performed below average on the Peabody Developmental Motor Scale (Second Edition) for object manipulation, which was attributed to decreased upper‐ and lower‐body strength. Although her concurrent neurological examination did not reveal any motor weakness, she reported easy fatigability, low energy, and difficulty coping with physical activity, for which she received physiotherapy and occupational therapy. By age 5 years 4 months, her development, including motor coordination, was reported to be normal, and by age 10 years, she demonstrated significant improvement in her motor skills. At age 6 years, her speech assessment showed age‐appropriate speech and language development. Currently, she exhibits normal growth, with the last recorded measurements at age 16 years: weight of 57.9 kg (60th percentile) and height of 166.5 cm (75th percentile). Neurological examination findings were unremarkable. Although formal neurocognitive assessment was not performed, she demonstrated age‐appropriate development, academic performance, and cognitive function. Her biochemical investigations, including glucose, ammonia, lactate, ketones, CK, PAA, plasma ACP, and UOA, completely normalized outside MDEs. Case 2, at age 4 years 5 months, underwent speech and language assessment, which revealed age‐appropriate speech, language, and fluency. His developmental assessment using the Bayley Scales of Infant and Toddler Development (third edition)—Bayley‐III indicated below‐average cognitive abilities. The Adaptive and Behavioral Assessment System (second edition)—ABAS‐II could not be completed due to increasing fatigue and distractibility, which may explain the underestimation of his cognitive abilities. Ongoing developmental monitoring revealed age‐appropriate cognitive function; thus, additional support was not indicated. At age 14 years, case 2 exhibits a normal neurological examination and an unremarkable biochemical profile. His growth was within the normal range, with the last recorded measurements of weight 67.9 kg (84th percentile) and height 180.3 cm (94th percentile). He demonstrated normal development, academic performance, and cognitive abilities (formal neurocognitive assessment was not performed). Discussion Demographic Distribution and Age of Onset CA‐VA deficiency is a rare inherited metabolic disease caused by biallelic pathogenic variants of the CA5A gene. To date, 69 cases have been reported worldwide (Tables 2 and 3), including our own, spanning diverse backgrounds, with most cases originating from the Middle East and South Asia (23 cases each), suggesting founder mutations [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 27]. Around 81.2% of cases manifest before 2 years of age, with 66.7% presenting during the neonatal period, highlighting the impact of the physiological catabolism characteristic of this phase [3, 4, 5, 6, 7, 8, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 27]. Childhood presentations account for 11.6% with onset typically ranging from 2 to 5 years [4, 11, 14, 18, 25]. While two asymptomatic adults identified through familial segregation studies have been reported [3, 18], adult‐onset presentations have not been described, indicating a predominant pediatric presentation. The remaining three cases were diagnosed antenatally [9, 24]. TABLE 2Summary of CA‐VA cases reported in the literature: Focus on the genotype, molecular testing, initial presentation, newborn screening, biochemical profile, brain imaging and acute management during the initial MDE.ReferencesAncestry CA5A genotypeMolecular testingAge at initial presentationInitial presentationNewborn screeningBiochemical profile and neuroimagingAcute managementvan Karnebeek et al. [3] and Diez‐Fernandez et al. [4]Russian Compound Heterozygous c.555G>A (p.Lys185Lys) & (p.His155_Leu186del) in‐frame deletion of exon 4 CA5A Sanger sequencing & RT‐PCR4 DOL Hyperammonemia Elevated lactate Hypoglycemia Metabolic acidosis Ketonuria LFTs: normal. Not reported ACP: normal PAA: elevated glutamine, alanine and proline. Normal citrulline, ornithine and arginine Urine orotate: normal. UOA: elevated lactate, ketones, dicarboxylic aciduria, 3‐hydroxypropionic acid, 3‐hydroxyisovaleric acid, mild elevation in 3‐methylcrotonylglycine and propionylglycine IV lipids Protein‐free formula Carglumic acid Biotin van Karnebeek et al. [3] and Diez‐Fernandez et al. [4] a Pakistani Homozygous 4 kb deletion encompassing exon 6 (c.619‐3427_c.774+502del4078bp, p.Asp207Gln258del) CA5A Sanger sequencing18 months Hyperammonemia Elevated lactate Compensated metabolic acidosis Not reported ACP: normal PAA: normal glutamine, arginine, ornithine. Increased plasma alanine and proline Urine orotate: normal UOA: grossly increased lactate and ketones, moderately increased fumaric acid and 3‐hydroxyisovaleric acid, mildly increased 2‐a‐ketoglutaric acid IV fluidsDiez‐Fernandez et al. [4]Turkish Homozygous c.123G>A (p.Trp41*) CA5A & CA5B Sequencing4 DOL Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Hypoglycemia Not reported ACP: not reported PAA: normal glutamine UOA: elevated lactate, ketones and pyruvate Urine orotate: normal Carglumic acid used in parallel to other treatmentsDiez‐Fernandez et al. [4]Indian Homozygous c.458_459+22del24bp. (p.?) CA5A & CA5B Sequencing5 months Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose Not reported ACP: not reported PAA: normal glutamine UOA: massive ketonuria Urine orotate: normal Carglumic acid not usedDiez‐Fernandez et al. [4]Pakistani Homozygous c.555+4_555+183del1180bp (p.?) CA5A & CA5B Sequencing4 years Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Hypoglycemia Not reported ACP: not reported PAA: normal glutamine UOA: massively elevated 3‐hydroxybutyric acid Urine orotate: normal Carglumic acid not usedDiez‐Fernandez et al. [4]Bangladeshi Homozygous c.721G>A (p.Glu241Lys) CA5A & CA5B Sequencing5 DOL Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose Not reported ACP: not reported PAA: elevated glutamine UOA: Elevated lactic acid, acetoacetic acid, 3‐hydroxy butyrate acid, 3‐hydroxyisovaleric acid and dicarboxylic aciduria Urine orotate: normal Carglumic acid used in MDEDiez‐Fernandez et al. [4]Pakistani Homozygous c.721G>A (p.Glu241Lys) CA5A & CA5B Sequencing4 DOL Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose Not reported ACP: not reported PAA: elevated glutamine UOA: lactic aciduria, ketonuria, elevated pyruvate, 3‐hydroxypropionic acid and adipic acid Urine orotate: normal Carglumic acid used in MDE Hemofiltration Diez‐Fernandez et al. [4]Pakistani Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) CA5A & CA5B Sequencing2 DOL Hyperammonemia Elevated lactate Elevated ketones Mixed metabolic acidosis & respiratory alkalosis Hypoglycemia Not reported ACP: not reported PAA: elevated glutamine UOA: massive excretion of lactic acid and ketones, elevated adipic acid, 3‐hydroxyisovaleric acid, slightly elevated suberic and sebacic acid Urine orotate: normal Carglumic acid not used Hemofiltration Diez‐Fernandez et al. [4]Indian Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) CA5A & CA5B Sequencing20 months Hyperammonemia Elevated lactate Elevated ketones Glucose and blood gas not reported Not reported ACP: not reported PAA: glutamine 828 μM UOA: not reported Urine orotate: normal Carglumic acid not usedDiez‐Fernandez et al. [4]Pakistani Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) CA5A & CA5B Sequencing3 DOL Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose Not reported ACP: not reported PAA: elevated glutamine UOA: massive elevation in lactic acid and ketones, mild elevation in 3‐hydroxyisovaleric acid, 3‐hydroxypropionic acid, adipic acid and suberic acid Urine orotate: normal Not reportedDiez‐Fernandez et al. [4]Pakistani Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) CA5A & CA5B Sequencing3 DOL Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Glucose not reported Not reported ACP: not reported PAA: elevated glutamine UOA: not reported Urine orotate: normal Carglumic acid not used Hemofiltration Diez‐Fernandez et al. [4]Pakistani Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) CA5A & CA5B Sequencing2 DOL Hyperammonemia Elevated lactate Elevated ketones Mixed metabolic acidosis with respiratory alkalosis Normal glucose Not reported ACP: not reported PAA: elevated glutamine UOA: lactate and ketones grossly elevated, moderate elevation in 3‐hydroxyisovaleric acid and adipic acid, traces of propionylglycine and 3‐methylcrotonylglycine Urine orotate: normal Carglumic acid used in parallel to other treatments Hemofiltration Baertling et al. [5]Not reported Homozygous Deletion of exons 1 and 2 WES18 months Seizures Arterial hypertension Hypoglycemia Elevated lactate Hyperammonemia Not reported ACP: not reported PAA: not reported UOA: not reported Brain MRI: initially normal. Repeat: severe brain herniation MRS: lactate peak in the basal ganglia IV Dextrose Protein and fat restriction Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine Carglumic acid Konanki et al. [6]Indian Homozygous c.721G>A (p.Glu241Lys) WES3 DOL Hyperammonemia Mixed metabolic acidosis and respiratory alkalosis Elevated lactate Hypoglycemia Normal urine ketones Mildly elevated LFTs Not reported PAA: mild elevation in tyrosine and phenylalanine ACP: normal. UOA: phenylalanine and tyrosine metabolites Brain MRI: T2 and T2 FLAIR Hyperintensities with loss of gray‐white matter differentiation. Areas of diffusion restriction involving the frontal parietal and medial occipital subcortical WM EEG: diffuse cerebral dysfunction IV Dextrose Sodium benzoate (500 mg/kg/day) Protein restriction (1 g/kg/day) Konanki et al. [6] b Indian Compound heterozygous c.788G>A (p.Arg263His) & c.868C>T (p.Arg290Trp). WES8 months Hyperammonemia Elevated lactate Metabolic acidosis Episodes of hypoglycemia Not reportedNot reported IV Dextrose Sodium benzoate (250 mg/kg/day) Konanki et al. [6]Indian Homozygous c.*‐56_143–1_143+1del WES2 DOL Hyperammonemia Elevated lactate Hypoglycemia Metabolic acidosis No ketonuria Not reported ACP: normal PAA: elevated alanine and proline UOA: lactic acid, a‐2‐ketoglutaric acid, pyruvic acid, 3‐hydroxybutyric acid Peritoneal dialysis Sodium benzoate (250 mg/kg/day) IV carnitine Oral bicarbonate Olgac et al. [7]Turkish Homozygous c.721G>A (p.Glu241Lys) WES2 DOL Hyperammonemia Hypoglycemia Elevated lactate HAGMA Severe ketonuria Hypernatremic dehydration Increased creatinine and BUN Not reported ACP: normal PAA: increased glutamine and alanine. Normal arginine, ornithine and citrulline UOA: increased lactic acid, pyruvic acid and ketone bodies. Normal 3‐hydroxypropionic acid, methyl citrate, 3‐methyl‐crotonylglycine and 3‐hydroxyisovaleric acid IV Dextrose (GIR 10 mg/kg/min) Sodium benzoate (250 mg/kg/day) Bicarbonate infusion l‐carnitine Biotin Hydroxocobalamin Carglumic acid Hemofiltration Marwaha et al. [8]Sri‐Lankan Homozygous c.721G>A (p.Glu241Lys) CA5A targeted gene sequencing3 DOL Hyperammonemia Elevated lactate Massive ketonuria HAGMA Normal ACP: low free and total carnitine PAA: elevated alanine. Normal arginine and citrulline UOA: lactic and ketoaciduria, dicarboxylic aciduria, liver metabolites Brain MRI: laminar subdural hematomas in the parietooccipital regions, posterior fossa, and posterior falx. Nonspecific hyperintensities in the deep WM in frontal, parietal and occipital lobes IV Dextrose Bicarbonate infusion Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine l‐carnitine Carglumic acid Marwaha et al. [8] and Ibrahim et al. [9]Indian Compound heterozygous c.721G>A (p.Glu241Lys) & c.619‐?_774+?del Hyperammonemia gene panel Confirmed by Sanger sequencing and qPCR 2 DOL Hyperammonemia Hypoglycemia Mixed metabolic acidosis and respiratory alkalosis Elevated lactate Elevated ketones Normal ACP: low free carnitine, elevated C4‐OH and C6‐OH PAA: elevated alanine and glutamine. Low arginine. Normal citrulline UOA: massive lactic aciduria, ketonuria, dicarboxylic aciduria, 3‐hydroxy‐3‐methylsuccinic aciduria, pyruvic aciduria, 3‐hydroxyisovaleric acid. Mild elevation in 3‐methylcrotonylglycine, tiglylglycine, and 2‐ethyl‐3‐hydroxypropionic acid Orotic acid slightly elevated Brain MRI (4 DOL): normal IV Dextrose IV lipids Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine Carglumic acid (100 mg) Biotin (5 mg) Hemofiltration Miller et al. [10] c Not reported Compound heterozygous Out‐of‐frame deletion spanning exon 3 & c.473A>C p.(His158Pro) Hyperammonemia gene panel Deletion/duplication analysis of CA5A 4 DOL Hyperammonemia Lactic acidosis Not reportedNot reported Low protein feeds l‐carnitine Miller et al. [10] c Not reported Compound heterozygous Out‐of‐frame deletion spanning exon 3 & c.473A>C p.(His158Pro). Hyperammonemia gene panel Deletion/duplication analysis of CA5A 19 months Hyperammonemia Elevated lactate Hypoglycemia Ketonuria Metabolic acidosis Normal ACP: not reported PAA: low arginine, citrulline and ornithine with high alanine and proline, normal glutamine UOA: increased lactate, ketones, 3‐hydroxypropionic acid and 3‐methylcrotonylglycine Brain MRI: T2 FLAIR signal abnormalities in the bifrontal cortex and bilateral medial occipital cortex MRS: elevated glutamate and lactate IV Dextrose (8 mg/kg/min) IV insulin (0.05 unit/kg/h) Nitrogen scavengers (sodium benzoate and sodium phenylacetate 250 mg/kg/day) l‐arginine HCl (200 mg/kg/day) Sredkova et al. [11] (Poster Presentation ICIEM 2021)Not reported Compound heterozygous c.555G>A (p.Lys185 =) & deletion in exon 1 WES followed by CA5A gene analysis for deletion and duplication assessment3‐years‐7‐months Hyperammonemia Hyperglycemia Elevated lactate Metabolic acidosis switched to respiratory alkalosis Normal liver function tests Not reported ACP: not reported PAA: not reported UOA: elevated lactate, ketone bodies and 3‐methylcrotonylglycinuria IV Dextrose Sodium phenylbutyrate l‐arginine HCl l‐carnitine Carglumic acid Singanamalla et al. [12]Indian Compound heterozygous c.123G>T (p.Trp41Cys) & c.690C>T (p.Tyr230 =) WES Confirmed by Sanger sequencing 3 DOL Cardiac arrest and cyanosis Hyperammonemia Elevated lactate Metabolic acidosis Ketonuria Normal glucose Not reported ACP: normal PAA: normal UOA: normal Brain MRI: normal IV Dextrose Sodium benzoate Carnitine Biotin Riboflavin Folic acid Zinc Sequeira [13]Caucasian Compound heterozygous c.774G>A (p.Gln258His) & c.(142+1_143–1)_(459+1_460–1)del (p.?) CA5A gene sequencing with MLPA2 DOL Hyperammonemia Metabolic acidosis Elevated lactate Hypoglycemia Elevated ketones Normal ACP: not reported PAA: elevated glutamine and alanine, low/normal citrulline. UOA: normal IV Dextrose Protein‐free formula Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine Carglumic acid (used with rebound hypoglycemia) Stockdale et al. [14]Not reported Homozygous c.619_3420_c.774+502del4078pb (p.Asp207_Gln258del) GA5A targeted gene sequencing2‐years‐8‐months Hyperammonemia Elevated lactate Ketonuria Not reported ACP: evidence of ketogenesis PAA: normal glutamine and alanine on initial presentation Urine orotic acid: normal UOA: ketonuria Brain MRI: bilateral cerebral cortical cytotoxic edema Nitrogen scavengers Carglumic acid (single dose) Ibrahim et al. [9]Indian Compound heterozygous c.721G>A (p.Glu241Lys) c.619‐?_774+?del FVT Diagnosed antenatally N/AN/ANot reported ACP: not reported PAA: not reported UOA: normal IV Dextrose IV lipids (2 g/kg/day) Carglumic acid (100 mg/kg twice daily) Semenova et al. [15]Russian Homozygous c.555G>A, p.Lys185Lys WGS Confirmed by Sanger sequencing 3 DOL Seizures Intestinal bleeding Significant liver disease Hypoglycemia Elevated lactate HAGMA Elevated ketones Elevated LFTs (×10 folds above normal) Not reported ACP: normal PAA: Elevated proline and alanine, normal citrulline, ornithine and arginine UOA: Mild elevation in pyruvate in urine, marked elevation in lactate, 3‐hydroxybutyric acid and 2‐ketoglutaric acid EEG: Diffuse cerebral dysfunction, electrographic generalized seizures IV fluids Bicarbonate l‐carnitine Cytoflavin (succinic acid, nicotinamide, inosine & riboflavin) Urmila et al. [16] d Indian Homozygous c.59G>A (p.Trp20*). WES3 DOL Refractory seizures (tonic & multi‐focal clonic seizures) Neonatal Hypoglycemia Elevated lactate Hyperammonemia Not reported ACP: normal PAA: not reported UOA: normal Brain MRI: mild cortical atrophy EEG: not available IV Dextrose Multiple AEMs Inotropes for poor perfusion Ganesh and Narayanan [17] d Indian Homozygous Missense mutation in exon 6 Not reported3 months Generalized seizures Moderate hepatomegaly Hyperammonemia Metabolic acidosis Elevated lactate Elevated LFTs Not reported ACP: normal PAA: normal UOA: normal. Brain MRI: normal IV fluids Sodium benzoate Carnitine Bicarbonate Peritoneal dialysis Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) WES1 DOL Hyperammonemia Elevated lactate Normal ketones Normal blood glucose Elevated CK Not reported ACP: not reported PAA: significantly elevated glutamine, proline, alanine and mildly elevated methionine UOA: lactic aciduria, ketonuria and mild elevation in 3‐hydroxyisovaleric acid Brain MRI: brain edema with focal areas of diffusion restriction in the right lentiform nucleus and the right thalamus in keeping with acute infarcts Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) WES4 DOL Hyperammonemia Elevated lactate Hypoglycemia Normal ketones Elevated CK Not reported ACP: not reported PAA: Isolated elevated ornithine UOA: lactic aciduria, ketonuria, 3‐hydroxyisovaleric aciduria Brain MRI (9 DOL): abnormal T2 signal intensity and diffusion restriction in the periorlandic cortex, insula, and basal ganglia in keeping with hyperammonemic encephalopathy Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e , f Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Hyperammonemia Elevated lactate Hypoglycemia Normal ketones Elevated CK Not reported ACP: not reported PAA: normal UOA: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e , f Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing2 DOL Hyperammonemia Elevated lactate Normal ketones Not reported ACP: not reported PAA: normal UOA: not reported Brain MRI: Changes consistent with hyperammonemic encephalopathy Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Hyperammonemia Elevated lactate Normal ketones Elevated CK Not reported ACP: not reported PAA: normal UOA: not reported Brain CT: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Hyperammonemia Elevated lactate Normal ketones Not reported ACP: not reported PAA: normal UOA: not reported Brain CT: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing2 DOL Hyperammonemia Blood glucose, ketones and lactate were not reported Not reported ACP: not reported PAA: normal UOA: not reported Brain CT: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Hyperammonemia Blood glucose, ketones and lactate were not reported Not reported ACP: not reported PAA: normal UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing5 years Hyperammonemia Elevated lactate Hypoglycemia Normal ketones Not reported ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) WES2 DOL Hyperammonemia Elevated lactate Elevated CK Normal glucose Normal ketones Not reported ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Hyperammonemia Elevated lactate Elevated ketones Elevated CK Normal glucose Not reported ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18]Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Elevated CK Ammonia, lactate, glucose and ketones are not reported Not reported ACP: not reported PAA: not reported UOA: not reported Not reportedAl‐Thihli et al. [18]Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Elevated CK Ammonia, lactate, glucose and ketones are not reported Not reported ACP: not reported PAA: not reported UOA: not reported Not reportedAl‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing3 DOL Hyperammonemia CK, lactate, glucose and ketones are not reported Not reported ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] g Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencingN/A Ammonia normal Lactate, glucose, CK and ketones are not reported Not reportedN/AN/AAl‐Thihli et al. [18] g Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencingN/A Ammonia normal Lactate, glucose, CK and ketones are not reported Not reportedN/AN/AAl‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) GA5A targeted gene sequencing4 years Hyperammonemia Elevated lactate Elevated ketones Normal glucose Normal CK Not reported ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Al‐Thihli et al. [18] e Omani Homozygous c.59G>A (p.Trp20*) WES18 months Hyperammonemia Elevated lactate Hypoglycemia Elevated ketones Elevated CK Not reported ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Mathew et al. [19]Indian Compound heterozygous c.721G>A (p.Glu241Lys) & c.619‐3420_c.774+502del4078bp spanning introns 5 & 6 and exon 6 WES followed by sanger sequencing for CA5A qPCR and LR‐PCR3 DOL Multifocal clonic seizures progressed into status epilepticus Metabolic acidosis with respiratory alkalosis Hyperammonemia Elevated lactate Elevated liver transaminases (mild) Normal ketones Normal glucose Normal CK Not reported ACP: not reported PAA: normal UOA: normal Brain MRI: WM hyperintensities in globus pallidus. MRS: choline peak IV fluids Inotropes (dopamine and adrenaline) AEM Phadke et al. [20]Indian Homozygous c.721G>A (p.Glu241Lys) WES4 DOL Hyperammonemia Hypoglycemia Elevated lactate Metabolic acidosis Not reported ACP: non diagnostic PAA: non diagnostic UOA: non diagnostic IV Dextrose Nitrogen scavengers (sodium benzoate) Peritoneal dialysis Majety et al. [21]Indian Homozygous c.721G>A (p.Glu241Lys) WES1 DOL Severe persistent metabolic acidosis hypoammonemia Elevated lactate Elevated ketones Normal glucose Normal LFTs Not reported ACP: Normal total carnitine with low free carnitine, normal acylcarnitine levels PAA: Elevated alanine, tyrosine, methionine and phenylalanine UOA: Elevated urine lactic acid, pyruvic acid and ketones IV fluids Bicarbonate infusion Inotropes Hydrocortisone Inhaled nitric oxide Abdulwahhab et al. [22]Indian Homozygous Deletion of exon 6 WES3 DOL Hyperammonemia Hypoglycemia Elevated lactate Elevated ketones HAGMA Not reported ACP: mild nonspecific elevations, normal carnitine levels PAA: Elevated alanine, glutamine and proline without accumulation of urea cycle products Urine orotic acid: normal UOA: Elevated pyruvate and pyroglutamic acid, elevated lactate and ketone bodies. IV Dextrose IV ammonia scavengers (sodium Benzoate and sodium phenylacetate) Carglumic acid (100 mg/kg/day) Biotin Riboflavin CoQ10 Feeding: EBM Hemofiltration for 24 h Keehan et al. [23]Guatemalan Homozygous c.475T>C (p.Trp159Arg) WES18 h Hyperammonemia Hypoglycemia HAGMA compensated with respiratory alkalosis Lactic acidosis Elevated ketones Normal PAA: elevated glutamine, glycine, alanine, proline, and asparagine. ACP: low free carnitine, elevated acetylcarnitine, non‐specific elevation in medium and long chain acylcarnitines secondary to mitochondrial dysfunction UOA: marked elevation in lactic acid and ketones IV Dextrose IV nitrogen scavengers (sodium Benzoate and sodium phenylacetate) IV l‐arginine HCl. l‐carnitine Cyanocobalamin Riboflavin Biotin Thiamine Manoy et al. [24]North American/Russian Compound Heterozygous c.198_208delins ACCCGG (p.Ile67Profs*13) & c.454G>A (p.Ala142Thr) Gene panel4 DOL Normal glucose HAGMA Hyperammonemia Lactic acidosis Elevated ketones Mildly elevated LFTs Normal PAA: Elevated glutamine and alanine. Normal citrulline and lysine. ACP: elevated 3‐hydroxybutyrylcarnitine, normal propionylcarnitine and isovalerylcarnitine UOA: elevated lactate, ketones, 2‐ketoisovalerate and 2‐ketoisocaproate IV glucose IV lipids Nitrogen scavengers Bicarbonate infusion Cofactor supplementation Carnitine supplementation Hemofiltration Manoy et al. [24]North American/Russian Compound Heterozygous c.198_208delins ACCCGG (p.Ile67Profs*13) & c.454G>A (p.Ala142Thr) FVT Diagnosed antenatally N/ANormal serial ammonia and blood gasNormalNot reported Delivery at tertiary hospital Strict breast feeding with supplementary formula/EBM Carglumic acid 100 mg/kg/day for 5 days Manoy et al. [24]North American/Russian Compound Heterozygous c.198_208delins ACCCGG (p.Ile67Profs*13) & c.454G>A (p.Ala142Thr) FVT Diagnosed antenatally N/A Mild respiratory distress Normal serial ammonia and blood gas NormalNot reported Delivery at tertiary hospital Strict breast feeding with supplementary formula/EBM. Carglumic acid 100 mg/kg/day for 5 days Bin Hadyan et al. [25]Saudi Homozygous Deletion involving exons 3–7 WES3 years Global developmental delay Axial hypotonia No history of MDEs Mildly elevated lactate Normal ammonia Not reportedNormal biochemical profile including PAA, ACP, UOAN/ABin Hadyan et al. [25] h Saudi Homozygous Deletion involving exons 3–7 WGS3 years Developmental delay affecting language and motor milestones No history of MDEs Normal ammonia, lactate, CK, LFTs and KFTs Not reported Normal biochemical profile including PAA, ACP, UOA Brain MRI: marked thinning of corpus callosum, mild periventricular leukomalacia N/ABin Hadyan et al. [25] i Saudi Homozygous Deletion involving exons 3–7 WGS4 years Mild speech delay No history of MDEs Normal ammonia, lactate, CK, LFTs and KFTs Not reported Normal biochemical profile including PAA, ACP, UOA Brain MRI: minor abnormalities N/AFragoso et al. [26]Not reported Compound heterozygous c.472C>T (p.His158Tyr) & c.556C>T (p.Leu186Phe) Not reported2 DOL Hyperammonemia Elevated lactate Normal glucose Not reported ACP: not reported PAA: elevated glutamine UOA: increased excretion of lactic acid, pyruvic acid and metabolites associated with ketosis Urine orotic acid: not detected Brain MRI: pattern consistent with hyperammonemia (selective involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex) Not reportedFragoso et al. [26]Not reported Homozygous Deletion of exon 1 Not reported3 DOL Hyperammonemia Elevated lactate Hypoglycemia Not reported ACP: not reported PAA: elevated glutamine UOA: increased excretion of lactic acid, pyruvic acid and metabolites associated with ketosis Urine orotic acid: not detected Brain MRI: pattern consistent with hyperammonemia (selective involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex) Not reportedFragoso et al. [26] j Not reported Homozygous c.742C>T Not reported3 months Severe tonic clonic seizures Hyperammonemia Elevated lactate Compensating metabolic acidosis Normal glucose Not reported ACP: not reported PAA: elevated glutamine UOA: increased excretion of lactic acid and metabolites associated with ketosis Urine orotic acid: not detected Brain MRI: extensive involvement affecting the basal ganglia and the brain stem Not reportedFragoso et al. [26]Not reported Homozygous Single exon deletion Not reported13 months Hyperammonemia Normal glucose Not reported ACP: not reported PAA: not reported UOA: increased metabolites associated with ketosis and other organic acids (secondary disturbances) Urine orotic acid: not detected Brain MRI: pattern consistent with hyperammonemia (selective involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex) Not reportedFragoso et al. [26]Not reported Homozygous c.59G>A (p.Trp20*) Not reported1 DOL Severe tonic clonic seizures Hyperammonemia Elevated lactate Normal glucose Not reported ACP: not reported PAA: not reported UOA: increased excretion of lactic acid, pyroglutamate, phenylacetic acid, 4‐OH‐phenyllactic acid, and 4‐OH‐phenylpyruvic acid Urine orotic acid: not detected Brain MRI: extensive involvement affecting the basal ganglia and the brain stem Not reportedFragoso et al. [26]Not reported Homozygous c.59G>A (p.Trp20*) Not reported4 DOL Hyperammonemia Elevated lactate Hypoglycemia Metabolic acidosis Not reported ACP: not reported PAA: normal UOA: not reported Brain MRI: involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex, extensive involvement affecting the basal ganglia and the brain stem Not reportedFragoso et al. [26]Not reported Homozygous c.59G>A (p.Trp20*) Not reported3 DOL Hyperammonemia Normal glucose Not reported ACP: not reported PAA: not reported UOA: not reported Brain MRI (2nd MDE): selective bilateral restriction diffusion in the claustrum. Not reportedFragoso et al. [26]Not reported Homozygous c.59G>A (p.Trp20*) Not reported6 DOL Hyperammonemia Elevated lactate Normal glucose Metabolic acidosis Not reported ACP: not reported PAA: not reported UOA: not reported Not reportedFragoso et al. [26] f , k Not reported Homozygous c.59G>A (p.Trp20*) Not reported3 DOL Hyperammonemia Elevated lactate Severe recurrent hypoglycemia Not reported ACP: not reported PAA: not reported UOA: not reported Brain MRI: involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex, extensive involvement affecting the basal ganglia and the brain stem Not reportedAbbreviations: ACP, acylcarnitine profile; BUN, blood urea nitrogen; BW, birth weight; CK, creatinine kinase; EBM, expressed breast milk; FVT, familial variant testing; HAGMA, high anion gap metabolic acidosis; KFTs, kidney function tests; LFTs, liver function tests; LR‐PCR, long‐range polymerase chain reaction; MDEs, metabolic decompensation episodes; MLPA, multiplex ligation‐dependent probe amplification; N/A, not applicable; OA, organic acidemias; qPCR, quantitative polymerase chain reaction; UCD, urea cycle defects; UOA, urine organic acids; WES, whole exome sequencing; WGS, whole genome sequencing; WM, white matter. a Patient's older brother (17 years) was homozygous for the same variant and declined further follow up. Prior MDEs cannot be excluded given the limited history. b Muscle biopsy: complex 1 deficiency. c Initial hyperammonemia gene panel missed the deletion in the second allele. d Unclear whether these investigations were obtained during the MDE or after treatment. e The paper did not specify treatment modalities for each patient. f Patients have a concurrent diagnosis of medium chain acyl‐coenzyme A dehydrogenase (MCAD) deficiency. g Asymptomatic adults diagnosed via cascade family testing. h Patient also had two other likely pathogenic variants: SYT2 (homozygous) causes AD/AR congenital myasthenia syndrome 7A/7B and SYNE4 (heterozygous) causes AR deafness. No clinical correlation was found. i Patient also had two other likely pathogenic variants: SYT2 (homozygous) AD/AR congenital myasthenia syndrome7A/7B & SYNE4 (homozygous) causes AR deafness. No clinical correlation was found. j Patient has CPS1 variant (c.2549C>T, p.Arg850Leu)—not diagnostic. k Patient is homozygous for ACADM variant (c.449_452del, p.Thr150Argfs*). Summary of CA‐VA cases reported in the literature: Focus on the genotype, molecular testing, initial presentation, newborn screening, biochemical profile, brain imaging and acute management during the initial MDE. Compound Heterozygous c.555G>A (p.Lys185Lys) & (p.His155_Leu186del) in‐frame deletion of exon 4 Hyperammonemia Elevated lactate Hypoglycemia Metabolic acidosis Ketonuria LFTs: normal. ACP: normal PAA: elevated glutamine, alanine and proline. Normal citrulline, ornithine and arginine Urine orotate: normal. UOA: elevated lactate, ketones, dicarboxylic aciduria, 3‐hydroxypropionic acid, 3‐hydroxyisovaleric acid, mild elevation in 3‐methylcrotonylglycine and propionylglycine IV lipids Protein‐free formula Carglumic acid Biotin Homozygous 4 kb deletion encompassing exon 6 (c.619‐3427_c.774+502del4078bp, p.Asp207Gln258del) Hyperammonemia Elevated lactate Compensated metabolic acidosis ACP: normal PAA: normal glutamine, arginine, ornithine. Increased plasma alanine and proline Urine orotate: normal UOA: grossly increased lactate and ketones, moderately increased fumaric acid and 3‐hydroxyisovaleric acid, mildly increased 2‐a‐ketoglutaric acid Homozygous c.123G>A (p.Trp41*) Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Hypoglycemia ACP: not reported PAA: normal glutamine UOA: elevated lactate, ketones and pyruvate Urine orotate: normal Homozygous c.458_459+22del24bp. (p.?) Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose ACP: not reported PAA: normal glutamine UOA: massive ketonuria Urine orotate: normal Homozygous c.555+4_555+183del1180bp (p.?) Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Hypoglycemia ACP: not reported PAA: normal glutamine UOA: massively elevated 3‐hydroxybutyric acid Urine orotate: normal Homozygous c.721G>A (p.Glu241Lys) Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose ACP: not reported PAA: elevated glutamine UOA: Elevated lactic acid, acetoacetic acid, 3‐hydroxy butyrate acid, 3‐hydroxyisovaleric acid and dicarboxylic aciduria Urine orotate: normal Homozygous c.721G>A (p.Glu241Lys) Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose ACP: not reported PAA: elevated glutamine UOA: lactic aciduria, ketonuria, elevated pyruvate, 3‐hydroxypropionic acid and adipic acid Urine orotate: normal Carglumic acid used in MDE Hemofiltration Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) Hyperammonemia Elevated lactate Elevated ketones Mixed metabolic acidosis & respiratory alkalosis Hypoglycemia ACP: not reported PAA: elevated glutamine UOA: massive excretion of lactic acid and ketones, elevated adipic acid, 3‐hydroxyisovaleric acid, slightly elevated suberic and sebacic acid Urine orotate: normal Carglumic acid not used Hemofiltration Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) Hyperammonemia Elevated lactate Elevated ketones Glucose and blood gas not reported ACP: not reported PAA: glutamine 828 μM UOA: not reported Urine orotate: normal Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Normal glucose ACP: not reported PAA: elevated glutamine UOA: massive elevation in lactic acid and ketones, mild elevation in 3‐hydroxyisovaleric acid, 3‐hydroxypropionic acid, adipic acid and suberic acid Urine orotate: normal Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) Hyperammonemia Elevated lactate Elevated ketones Metabolic acidosis Glucose not reported ACP: not reported PAA: elevated glutamine UOA: not reported Urine orotate: normal Carglumic acid not used Hemofiltration Homozygous c.619‐3427_c.774+502del4078bp, (p.Asp207Gln258del) Hyperammonemia Elevated lactate Elevated ketones Mixed metabolic acidosis with respiratory alkalosis Normal glucose ACP: not reported PAA: elevated glutamine UOA: lactate and ketones grossly elevated, moderate elevation in 3‐hydroxyisovaleric acid and adipic acid, traces of propionylglycine and 3‐methylcrotonylglycine Urine orotate: normal Carglumic acid used in parallel to other treatments Hemofiltration Homozygous Deletion of exons 1 and 2 Seizures Arterial hypertension Hypoglycemia Elevated lactate Hyperammonemia ACP: not reported PAA: not reported UOA: not reported Brain MRI: initially normal. Repeat: severe brain herniation MRS: lactate peak in the basal ganglia IV Dextrose Protein and fat restriction Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine Carglumic acid Homozygous c.721G>A (p.Glu241Lys) Hyperammonemia Mixed metabolic acidosis and respiratory alkalosis Elevated lactate Hypoglycemia Normal urine ketones Mildly elevated LFTs PAA: mild elevation in tyrosine and phenylalanine ACP: normal. UOA: phenylalanine and tyrosine metabolites Brain MRI: T2 and T2 FLAIR Hyperintensities with loss of gray‐white matter differentiation. Areas of diffusion restriction involving the frontal parietal and medial occipital subcortical WM EEG: diffuse cerebral dysfunction IV Dextrose Sodium benzoate (500 mg/kg/day) Protein restriction (1 g/kg/day) Compound heterozygous c.788G>A (p.Arg263His) & c.868C>T (p.Arg290Trp). Hyperammonemia Elevated lactate Metabolic acidosis Episodes of hypoglycemia IV Dextrose Sodium benzoate (250 mg/kg/day) Homozygous c.*‐56_143–1_143+1del Hyperammonemia Elevated lactate Hypoglycemia Metabolic acidosis No ketonuria ACP: normal PAA: elevated alanine and proline UOA: lactic acid, a‐2‐ketoglutaric acid, pyruvic acid, 3‐hydroxybutyric acid Peritoneal dialysis Sodium benzoate (250 mg/kg/day) IV carnitine Oral bicarbonate Homozygous c.721G>A (p.Glu241Lys) Hyperammonemia Hypoglycemia Elevated lactate HAGMA Severe ketonuria Hypernatremic dehydration Increased creatinine and BUN ACP: normal PAA: increased glutamine and alanine. Normal arginine, ornithine and citrulline UOA: increased lactic acid, pyruvic acid and ketone bodies. Normal 3‐hydroxypropionic acid, methyl citrate, 3‐methyl‐crotonylglycine and 3‐hydroxyisovaleric acid IV Dextrose (GIR 10 mg/kg/min) Sodium benzoate (250 mg/kg/day) Bicarbonate infusion l‐carnitine Biotin Hydroxocobalamin Carglumic acid Hemofiltration Homozygous c.721G>A (p.Glu241Lys) Hyperammonemia Elevated lactate Massive ketonuria HAGMA ACP: low free and total carnitine PAA: elevated alanine. Normal arginine and citrulline UOA: lactic and ketoaciduria, dicarboxylic aciduria, liver metabolites Brain MRI: laminar subdural hematomas in the parietooccipital regions, posterior fossa, and posterior falx. Nonspecific hyperintensities in the deep WM in frontal, parietal and occipital lobes IV Dextrose Bicarbonate infusion Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine l‐carnitine Carglumic acid Compound heterozygous c.721G>A (p.Glu241Lys) & c.619‐?_774+?del Hyperammonemia gene panel Confirmed by Sanger sequencing and qPCR Hyperammonemia Hypoglycemia Mixed metabolic acidosis and respiratory alkalosis Elevated lactate Elevated ketones ACP: low free carnitine, elevated C4‐OH and C6‐OH PAA: elevated alanine and glutamine. Low arginine. Normal citrulline UOA: massive lactic aciduria, ketonuria, dicarboxylic aciduria, 3‐hydroxy‐3‐methylsuccinic aciduria, pyruvic aciduria, 3‐hydroxyisovaleric acid. Mild elevation in 3‐methylcrotonylglycine, tiglylglycine, and 2‐ethyl‐3‐hydroxypropionic acid Orotic acid slightly elevated Brain MRI (4 DOL): normal IV Dextrose IV lipids Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine Carglumic acid (100 mg) Biotin (5 mg) Hemofiltration Compound heterozygous Out‐of‐frame deletion spanning exon 3 & c.473A>C p.(His158Pro) Hyperammonemia gene panel Deletion/duplication analysis of CA5A Hyperammonemia Lactic acidosis Low protein feeds l‐carnitine Compound heterozygous Out‐of‐frame deletion spanning exon 3 & c.473A>C p.(His158Pro). Hyperammonemia gene panel Deletion/duplication analysis of CA5A Hyperammonemia Elevated lactate Hypoglycemia Ketonuria Metabolic acidosis ACP: not reported PAA: low arginine, citrulline and ornithine with high alanine and proline, normal glutamine UOA: increased lactate, ketones, 3‐hydroxypropionic acid and 3‐methylcrotonylglycine Brain MRI: T2 FLAIR signal abnormalities in the bifrontal cortex and bilateral medial occipital cortex MRS: elevated glutamate and lactate IV Dextrose (8 mg/kg/min) IV insulin (0.05 unit/kg/h) Nitrogen scavengers (sodium benzoate and sodium phenylacetate 250 mg/kg/day) l‐arginine HCl (200 mg/kg/day) Compound heterozygous c.555G>A (p.Lys185 =) & deletion in exon 1 Hyperammonemia Hyperglycemia Elevated lactate Metabolic acidosis switched to respiratory alkalosis Normal liver function tests ACP: not reported PAA: not reported UOA: elevated lactate, ketone bodies and 3‐methylcrotonylglycinuria IV Dextrose Sodium phenylbutyrate l‐arginine HCl l‐carnitine Carglumic acid Compound heterozygous c.123G>T (p.Trp41Cys) & c.690C>T (p.Tyr230 =) WES Confirmed by Sanger sequencing Cardiac arrest and cyanosis Hyperammonemia Elevated lactate Metabolic acidosis Ketonuria Normal glucose ACP: normal PAA: normal UOA: normal Brain MRI: normal IV Dextrose Sodium benzoate Carnitine Biotin Riboflavin Folic acid Zinc Compound heterozygous c.774G>A (p.Gln258His) & c.(142+1_143–1)_(459+1_460–1)del (p.?) Hyperammonemia Metabolic acidosis Elevated lactate Hypoglycemia Elevated ketones ACP: not reported PAA: elevated glutamine and alanine, low/normal citrulline. UOA: normal IV Dextrose Protein‐free formula Nitrogen scavengers (sodium benzoate and sodium phenylacetate) l‐arginine Carglumic acid (used with rebound hypoglycemia) Homozygous c.619_3420_c.774+502del4078pb (p.Asp207_Gln258del) Hyperammonemia Elevated lactate Ketonuria ACP: evidence of ketogenesis PAA: normal glutamine and alanine on initial presentation Urine orotic acid: normal UOA: ketonuria Brain MRI: bilateral cerebral cortical cytotoxic edema Nitrogen scavengers Carglumic acid (single dose) Compound heterozygous c.721G>A (p.Glu241Lys) c.619‐?_774+?del FVT Diagnosed antenatally ACP: not reported PAA: not reported UOA: normal IV Dextrose IV lipids (2 g/kg/day) Carglumic acid (100 mg/kg twice daily) Homozygous c.555G>A, p.Lys185Lys WGS Confirmed by Sanger sequencing Seizures Intestinal bleeding Significant liver disease Hypoglycemia Elevated lactate HAGMA Elevated ketones Elevated LFTs (×10 folds above normal) ACP: normal PAA: Elevated proline and alanine, normal citrulline, ornithine and arginine UOA: Mild elevation in pyruvate in urine, marked elevation in lactate, 3‐hydroxybutyric acid and 2‐ketoglutaric acid EEG: Diffuse cerebral dysfunction, electrographic generalized seizures IV fluids Bicarbonate l‐carnitine Cytoflavin (succinic acid, nicotinamide, inosine & riboflavin) Homozygous c.59G>A (p.Trp20*). Refractory seizures (tonic & multi‐focal clonic seizures) Neonatal Hypoglycemia Elevated lactate Hyperammonemia ACP: normal PAA: not reported UOA: normal Brain MRI: mild cortical atrophy EEG: not available IV Dextrose Multiple AEMs Inotropes for poor perfusion Homozygous Missense mutation in exon 6 Generalized seizures Moderate hepatomegaly Hyperammonemia Metabolic acidosis Elevated lactate Elevated LFTs ACP: normal PAA: normal UOA: normal. Brain MRI: normal IV fluids Sodium benzoate Carnitine Bicarbonate Peritoneal dialysis Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Normal ketones Normal blood glucose Elevated CK ACP: not reported PAA: significantly elevated glutamine, proline, alanine and mildly elevated methionine UOA: lactic aciduria, ketonuria and mild elevation in 3‐hydroxyisovaleric acid Brain MRI: brain edema with focal areas of diffusion restriction in the right lentiform nucleus and the right thalamus in keeping with acute infarcts Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Hypoglycemia Normal ketones Elevated CK ACP: not reported PAA: Isolated elevated ornithine UOA: lactic aciduria, ketonuria, 3‐hydroxyisovaleric aciduria Brain MRI (9 DOL): abnormal T2 signal intensity and diffusion restriction in the periorlandic cortex, insula, and basal ganglia in keeping with hyperammonemic encephalopathy Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Hypoglycemia Normal ketones Elevated CK ACP: not reported PAA: normal UOA: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Normal ketones ACP: not reported PAA: normal UOA: not reported Brain MRI: Changes consistent with hyperammonemic encephalopathy Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Normal ketones Elevated CK ACP: not reported PAA: normal UOA: not reported Brain CT: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Normal ketones ACP: not reported PAA: normal UOA: not reported Brain CT: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Blood glucose, ketones and lactate were not reported ACP: not reported PAA: normal UOA: not reported Brain CT: normal Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Blood glucose, ketones and lactate were not reported ACP: not reported PAA: normal UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Hypoglycemia Normal ketones ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Elevated CK Normal glucose Normal ketones ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Elevated ketones Elevated CK Normal glucose ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Elevated CK Ammonia, lactate, glucose and ketones are not reported ACP: not reported PAA: not reported UOA: not reported Homozygous c.59G>A (p.Trp20*) Elevated CK Ammonia, lactate, glucose and ketones are not reported ACP: not reported PAA: not reported UOA: not reported Homozygous c.59G>A (p.Trp20*) Hyperammonemia CK, lactate, glucose and ketones are not reported ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Ammonia normal Lactate, glucose, CK and ketones are not reported Homozygous c.59G>A (p.Trp20*) Ammonia normal Lactate, glucose, CK and ketones are not reported Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Elevated ketones Normal glucose Normal CK ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Hypoglycemia Elevated ketones Elevated CK ACP: not reported PAA: not reported UOA: not reported Ammonia scavenger (sodium benzoate & sodium phenylbutyrate) Carglumic acid (ammonia normalized within 24 h when used alone) Compound heterozygous c.721G>A (p.Glu241Lys) & c.619‐3420_c.774+502del4078bp spanning introns 5 & 6 and exon 6 Multifocal clonic seizures progressed into status epilepticus Metabolic acidosis with respiratory alkalosis Hyperammonemia Elevated lactate Elevated liver transaminases (mild) Normal ketones Normal glucose Normal CK ACP: not reported PAA: normal UOA: normal Brain MRI: WM hyperintensities in globus pallidus. MRS: choline peak IV fluids Inotropes (dopamine and adrenaline) AEM Homozygous c.721G>A (p.Glu241Lys) Hyperammonemia Hypoglycemia Elevated lactate Metabolic acidosis ACP: non diagnostic PAA: non diagnostic UOA: non diagnostic IV Dextrose Nitrogen scavengers (sodium benzoate) Peritoneal dialysis Homozygous c.721G>A (p.Glu241Lys) Severe persistent metabolic acidosis hypoammonemia Elevated lactate Elevated ketones Normal glucose Normal LFTs ACP: Normal total carnitine with low free carnitine, normal acylcarnitine levels PAA: Elevated alanine, tyrosine, methionine and phenylalanine UOA: Elevated urine lactic acid, pyruvic acid and ketones IV fluids Bicarbonate infusion Inotropes Hydrocortisone Inhaled nitric oxide Homozygous Deletion of exon 6 Hyperammonemia Hypoglycemia Elevated lactate Elevated ketones HAGMA ACP: mild nonspecific elevations, normal carnitine levels PAA: Elevated alanine, glutamine and proline without accumulation of urea cycle products Urine orotic acid: normal UOA: Elevated pyruvate and pyroglutamic acid, elevated lactate and ketone bodies. IV Dextrose IV ammonia scavengers (sodium Benzoate and sodium phenylacetate) Carglumic acid (100 mg/kg/day) Biotin Riboflavin CoQ10 Feeding: EBM Hemofiltration for 24 h Homozygous c.475T>C (p.Trp159Arg) Hyperammonemia Hypoglycemia HAGMA compensated with respiratory alkalosis Lactic acidosis Elevated ketones PAA: elevated glutamine, glycine, alanine, proline, and asparagine. ACP: low free carnitine, elevated acetylcarnitine, non‐specific elevation in medium and long chain acylcarnitines secondary to mitochondrial dysfunction UOA: marked elevation in lactic acid and ketones IV Dextrose IV nitrogen scavengers (sodium Benzoate and sodium phenylacetate) IV l‐arginine HCl. l‐carnitine Cyanocobalamin Riboflavin Biotin Thiamine Compound Heterozygous c.198_208delins ACCCGG (p.Ile67Profs*13) & c.454G>A (p.Ala142Thr) Normal glucose HAGMA Hyperammonemia Lactic acidosis Elevated ketones Mildly elevated LFTs PAA: Elevated glutamine and alanine. Normal citrulline and lysine. ACP: elevated 3‐hydroxybutyrylcarnitine, normal propionylcarnitine and isovalerylcarnitine UOA: elevated lactate, ketones, 2‐ketoisovalerate and 2‐ketoisocaproate IV glucose IV lipids Nitrogen scavengers Bicarbonate infusion Cofactor supplementation Carnitine supplementation Hemofiltration Compound Heterozygous c.198_208delins ACCCGG (p.Ile67Profs*13) & c.454G>A (p.Ala142Thr) FVT Diagnosed antenatally Delivery at tertiary hospital Strict breast feeding with supplementary formula/EBM Carglumic acid 100 mg/kg/day for 5 days Compound Heterozygous c.198_208delins ACCCGG (p.Ile67Profs*13) & c.454G>A (p.Ala142Thr) FVT Diagnosed antenatally Mild respiratory distress Normal serial ammonia and blood gas Delivery at tertiary hospital Strict breast feeding with supplementary formula/EBM. Carglumic acid 100 mg/kg/day for 5 days Homozygous Deletion involving exons 3–7 Global developmental delay Axial hypotonia No history of MDEs Mildly elevated lactate Normal ammonia Homozygous Deletion involving exons 3–7 Developmental delay affecting language and motor milestones No history of MDEs Normal ammonia, lactate, CK, LFTs and KFTs Normal biochemical profile including PAA, ACP, UOA Brain MRI: marked thinning of corpus callosum, mild periventricular leukomalacia Homozygous Deletion involving exons 3–7 Mild speech delay No history of MDEs Normal ammonia, lactate, CK, LFTs and KFTs Normal biochemical profile including PAA, ACP, UOA Brain MRI: minor abnormalities Compound heterozygous c.472C>T (p.His158Tyr) & c.556C>T (p.Leu186Phe) Hyperammonemia Elevated lactate Normal glucose ACP: not reported PAA: elevated glutamine UOA: increased excretion of lactic acid, pyruvic acid and metabolites associated with ketosis Urine orotic acid: not detected Brain MRI: pattern consistent with hyperammonemia (selective involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex) Homozygous Deletion of exon 1 Hyperammonemia Elevated lactate Hypoglycemia ACP: not reported PAA: elevated glutamine UOA: increased excretion of lactic acid, pyruvic acid and metabolites associated with ketosis Urine orotic acid: not detected Brain MRI: pattern consistent with hyperammonemia (selective involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex) Homozygous c.742C>T Severe tonic clonic seizures Hyperammonemia Elevated lactate Compensating metabolic acidosis Normal glucose ACP: not reported PAA: elevated glutamine UOA: increased excretion of lactic acid and metabolites associated with ketosis Urine orotic acid: not detected Brain MRI: extensive involvement affecting the basal ganglia and the brain stem Homozygous Single exon deletion Hyperammonemia Normal glucose ACP: not reported PAA: not reported UOA: increased metabolites associated with ketosis and other organic acids (secondary disturbances) Urine orotic acid: not detected Brain MRI: pattern consistent with hyperammonemia (selective involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex) Homozygous c.59G>A (p.Trp20*) Severe tonic clonic seizures Hyperammonemia Elevated lactate Normal glucose ACP: not reported PAA: not reported UOA: increased excretion of lactic acid, pyroglutamate, phenylacetic acid, 4‐OH‐phenyllactic acid, and 4‐OH‐phenylpyruvic acid Urine orotic acid: not detected Brain MRI: extensive involvement affecting the basal ganglia and the brain stem Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Hypoglycemia Metabolic acidosis ACP: not reported PAA: normal UOA: not reported Brain MRI: involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex, extensive involvement affecting the basal ganglia and the brain stem Homozygous c.59G>A (p.Trp20*) Hyperammonemia Normal glucose ACP: not reported PAA: not reported UOA: not reported Brain MRI (2nd MDE): selective bilateral restriction diffusion in the claustrum. Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Normal glucose Metabolic acidosis ACP: not reported PAA: not reported UOA: not reported Homozygous c.59G>A (p.Trp20*) Hyperammonemia Elevated lactate Severe recurrent hypoglycemia ACP: not reported PAA: not reported UOA: not reported Brain MRI: involvement of cortical and juxtacortical regions of the insular/peri‐nsular area, Sylvian/peri‐Sylvian fissures, and the peri‐orlandic cortex, extensive involvement affecting the basal ganglia and the brain stem Abbreviations: ACP, acylcarnitine profile; BUN, blood urea nitrogen; BW, birth weight; CK, creatinine kinase; EBM, expressed breast milk; FVT, familial variant testing; HAGMA, high anion gap metabolic acidosis; KFTs, kidney function tests; LFTs, liver function tests; LR‐PCR, long‐range polymerase chain reaction; MDEs, metabolic decompensation episodes; MLPA, multiplex ligation‐dependent probe amplification; N/A, not applicable; OA, organic acidemias; qPCR, quantitative polymerase chain reaction; UCD, urea cycle defects; UOA, urine organic acids; WES, whole exome sequencing; WGS, whole genome sequencing; WM, white matter. Patient's older brother (17 years) was homozygous for the same variant and declined further follow up. Prior MDEs cannot be excluded given the limited history. Muscle biopsy: complex 1 deficiency. Initial hyperammonemia gene panel missed the deletion in the second allele. Unclear whether these investigations were obtained during the MDE or after treatment. The paper did not specify treatment modalities for each patient. Patients have a concurrent diagnosis of medium chain acyl‐coenzyme A dehydrogenase (MCAD) deficiency. Asymptomatic adults diagnosed via cascade family testing. Patient also had two other likely pathogenic variants: SYT2 (homozygous) causes AD/AR congenital myasthenia syndrome 7A/7B and SYNE4 (heterozygous) causes AR deafness. No clinical correlation was found. Patient also had two other likely pathogenic variants: SYT2 (homozygous) AD/AR congenital myasthenia syndrome7A/7B & SYNE4 (homozygous) causes AR deafness. No clinical correlation was found. Patient has CPS1 variant (c.2549C>T, p.Arg850Leu)—not diagnostic. Patient is homozygous for ACADM variant (c.449_452del, p.Thr150Argfs*). TABLE 3Summary of CA‐VA cases reported in the literature: Additional MDEs, long‐term follow‐up, neurological outcome and long‐term management.ReferencesNumber of additional MDEsAge of last reported MDEAge at the time of publicationTotal number of MDEsLong‐term follow‐up and neurological outcomeLong‐term managementDietary managementMedicationsvan Karnebeek et al. [3] and Diez‐Fernandez et al. [4]None4 DOL6 months1Normal growth and development On breast feeding, no protein restriction Sick‐day plan Continued Carglumic acid until 4 months, then discontinuedvan Karnebeek et al. [3] and Diez‐Fernandez et al. [4] a 116 months11 years2 Minor LD (no formal testing) Normal growth and good developmental progress Discharged on protein restriction after second MDEStarted on sodium benzoate and l‐arginine after the first MDE (at 16 months of age), treatment withdrawn at age 7 yearsDiez‐Fernandez et al. [4]None4 DOL12 months1NormalNot reportedNot reportedDiez‐Fernandez et al. [4] b 12 years10 years2NormalNot reportedNot reportedDiez‐Fernandez et al. [4] b 14‐years‐1‐month10 years2NormalNot reportedNot reportedDiez‐Fernandez et al. [4]None5 DOLNot reported1NormalNot reportedNot reportedDiez‐Fernandez et al. [4]None4 DOL3 years1NormalNoneNoneDiez‐Fernandez et al. [4] b 123 months6 years2NormalSick‐day planNoneDiez‐Fernandez et al. [4]None20 months4 years1NormalNot reportedNot reportedDiez‐Fernandez et al. [4]None3 DOL4 years1NormalNoneNoneDiez‐Fernandez et al. [4]None3 DOL5 years1 LD Speech delay Not reportedNot reportedDiez‐Fernandez et al. [4]None2 DOL9 months1NormalNoneNoneBaertling et al. [5]None18 months18 months1Patient passed away after the first MDE. Hyperammonemia and metabolic acidosis resolved in less than 24 h after the initial presentation. The encephalopathy and hypertension worsened even after the correction of the metabolic defects. He developed seizures on 3 DOA. Increased intracranial pressure was detected. Repeat MRI revealed severe brain herniation.N/AN/AKonanki et al. [6]None3 DOL18 months1Normal growth and developmentNo protein restriction (protein intake 2.5 g/kg/day)Not reportedKonanki et al. [6]Multiple22 months22 monthsMultiplePatient passed away during last MDEN/AN/AKonanki et al. [6] c None2 DOL4 months1Normal growth and developmentOn breast feeding. No protein restrictionSodium benzoateOlgac et al. [7]None2 DOL18 months1Normal growth and development Started on protein restriction after her first MDE. Later on, protein intake was liberalized outside MDEs. Sick‐day plan with protein restriction during illness Carglumic acid during illnessesMarwaha et al. [8]None3 DOL9 years1 Normal growth and development Biochemical profile normalized outside MDE Brain MRI: laminar subdural hematomas in the parietooccipital regions, posterior fossa, and posterior falx. Nonspecific hyperintensities in the deep WM in frontal, parietal and occipital lobes Regular mixed diet Sick‐day plan Discharged home on carnitine supplements (discontinued at the age of 3 months). Riboflavin (100–150 mg/day, discontinued at 3.6 years) No long‐term medications since the age of 3.6 years Marwaha et al. [8] d None2 DOL19 months1 Normal growth and development Biochemical profile normalized outside MDE Brain MRI 4 DOL: normal Regular mixed diet Sick‐day plan NoneMiller et al. [10]None4 DOL5 years1Normal growth and development Regular mixed diet Sick‐day plan NoneMiller et al. [10]None19 months3 years1 Normal growth and development Biochemical profile normalized outside MDE Regular mixed diet Sick‐day plan NoneSredkova et al. [11] (Poster Presentation ICIEM 2021)None3‐years‐7‐months3‐years‐7‐months1 Normal growth and development Normal biochemical investigations during febrile illnesses Low protein diet Sick‐day management (high calorie, lipid‐rich formula) l‐carnitineSinganamalla et al. [12] e None3 DOL18 months1 Normal growth and development Normal neurological examination Continued to have elevated ammonia and lactate outside MDEs Not reported Sodium benzoate Carnitine Riboflavin Zinc Sequeira [13]None2 DOL4‐years‐6‐months1Normal growth and developmentProtein restriction for 6 months after the initial MDE, followed by regular diet.Sodium benzoate for 6 months after the initial MDE, followed by regular diet.Stockdale et al. [14] f 65‐years‐9‐months5‐years‐9‐months7 Not reported. Brain MRI (MDE2): bilateral cerebral cortical cytotoxic edema Protein restriction (0.9–1 g/kg/day) Sick‐day plan Glycerol phenylbutyrate Sodium benzoate Ibrahim et al. [9]NoneN/A11 monthsNoneNormal growth and developmentRegular infant formulaNot reportedSemenova et al. [15]None3 DOL5 years1 Normal growth and development Normal ammonia, PAA and UOA EEG: multi‐regional epileptiform discharges Not reportedNoneUrmila et al. [16] g 13 DOL14 months1 At 7 months: abnormal movements, EEG suggestive of bilateral generalized epileptiform activity. At 8 months: infantile spasm & developmental delay Microcephaly, hypotonia Brain MRI: mild cortical atrophy EEG: modified hypsarrhythmia during sleep At 9 months: developmental delay, normal ammonia and lactate Sick‐day plan (IV dextrose, protein‐free diet, avoidance of fasting)AEMsGanesh and Nrayanan [17]None3 months18 months1 Normal development Normal biochemical profile Normal brain MRI Not reported Sodium benzoate Carnitine Al‐Thihli et al. [18] h Recurrent hyperammonemiaNot reported5 yearsMultiple GDD Microcephaly FTT Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18] h Recurrent hyperammonemiaNot reported5 yearsMultiple Severe GDD Microcephaly FTT Mild ammonia and lactate elevation outside MDE Not reportedNot reportedAl‐Thihli et al. [18] h Recurrent hyperammonemiaNot reported3 yearsMultiple GDD FTT Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None2 DOL1 year1 Normal neurodevelopment Normal HC FTT Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18] h Recurrent hyperammonemiaNot reported4 yearsMultiple Mild LD Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18] h Recurrent hyperammonemiaNot reported3 yearsMultiple Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18] h Recurrent hyperammonemia2 DOL7 yearsMultiple Normal neurodevelopment Normal HC FTT Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None3 DOL3 years1 Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None5 years5 years1 GDD Microcephaly FTT Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None2 DOL8 years1 Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None3 DOL4 years1 Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None3 DOL14 years1 Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None3 DOL17 years1 Normal neurodevelopment Normal HC FTT Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18]None3 DOL13 years1 Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18] i N/AN/A27 yearsN/A Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE N/AN/AAl‐Thihli et al. [18] i N/AN/A30 yearsN/A Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE N/AN/AAl‐Thihli et al. [18]None4 years4 years1 GDD Failure to thrive Normal HC Normal ammonia outside MDE Not reportedNot reportedAl‐Thihli et al. [18] h Recurrent hyperammonemiaNot reported14 yearsMultiple GDD Normal growth Normal HC Normal ammonia outside MDE Not reportedNot reportedMathew et al. [19]None3 DOL40 DOL1 Ongoing neurological abnormalities: central and peripheral hypotonia, poor suck. Brain MRI was not repeated after initial MDE Breast feedingAEM: Levetiracetam and phenytoinPhadke et al. [20]None4 DOL5 years1Normal growth and developmentNoneNoneMajety et al. [21]None2 DOL2 DOL1Patient deceasedN/AN/AAbdulwahhab et al. [22]None3 DOL5 weeks1Normal growth and developmentExclusive breast feeding. No protein restriction Carglumic acid Biotin Riboflavin CoQ10 Keehan et al. [23]None18 h4 months1 Normal development and growth Repeat PAA & UOA normalized NoneNoneManoy et al. [24]NoneN/A4 years1Normal growth and developmentInitially managed via protein restriction and carnitine supplementation (discontinued).NoneManoy et al. [24]NoneN/A3 yearsNoneNormal growth and developmentSick‐day protocol during illness.NoneManoy et al. [24]None4 DOL14 monthsNoneNormal growth and developmentSick‐day protocol during illness.NoneBin Hadyan et al. [25]NoneN/A4 yearsNone Axial hypotonia. GDD Normal growth Brain MRI: Marked thinning of corpus callosum. Mild periventricular leukomalacia N/AN/ABin Hadyan et al. [25]NoneN/A7 yearsNone Microcephaly (at 3rd centile). Continued to have significant speech delay, mild to moderate intellectual disability Motor skills improved Brain MRI: minor abnormalities N/AN/ABin Hadyan et al. [25]NoneN/A4 yearsNone Mild speech delay Normal growth and physical examination N/AN/AFragoso et al. [26]None2 DOL3 weeks1 Normal neurodevelopmental outcome Brain MRI (at 3 weeks): complete resolution of abnormalities found on initial MDE Not reportedNot reportedFragoso et al. [26]None3 DOL40 months1Normal neurodevelopmental outcomeNot reportedNot reportedFragoso et al. [26]11 year16 years2 LD Microcephaly Not reportedNot reportedFragoso et al. [26]None13 months24 months1 Normal neurodevelopmental outcome Brain MRI (11 months after initial MDE): mild residual gliotic changes in bilateral centrum semiovale and corona radiata, resolution of previously noted abnormalities Not reportedNot reportedFragoso et al. [26]None1 DOL7 years1 Severe GDD Axial hypotonia Central hypertonia Microcephaly Stereotypic behavior and autistic features Not reportedNot reportedFragoso et al. [26]None4 DOL14 months1 GDD Microcephaly Brain MRI (14 months after initial MDE): extensive residual gliotic changes in the bilateral periorlandic and insular cortices, subcortical WM, putamina, globi pallidi, and superior peduncles, new involvement of bilateral caudet heads and left thalamus Not reportedNot reportedFragoso et al. [26]16 years7 years2Normal neurodevelopmental outcomeNot reportedNot reportedFragoso et al. [26]None6 DOL6 months1Normal neurodevelopmental outcomeNot reportedNot reportedFragoso et al. [26] j None3 DOL24 months1 GDD Hypotonia Recurrent symptomatic hypoglycemia Not reportedNot reportedAbbreviations: DOA, day of admission; DOL, day of life; FTT, failure to thrive; GDD, global developmental delay; HC, head circumference; LD, learning difficulties; MDEs, metabolic decompensation episodes; WM, white matter. a Patient continued to have infrequent episodes of vomiting and ketoacidosis without hyperammonemia or elevated lactate. b Second MDE were milder than the initial MDE. c Patient was found to have elevated ammonia at 174 μmol/L on routine assessment at 1 month of age. No clinical symptoms were reported. d Patient also reported in Ibrahim et al. [9] at 2 years of age. e Patient was found to have elevated ammonia up to 340 μmol/L in routine assessment. f In 2 episodes, the patient required PICU admission and was on hemofiltration for ammonia detoxification. In episode 2, he had increased intracranial pressure and cerebral edema. g Patient presented with symptoms not usually seen in MDEs. No further details were provided in the report. h Patients with recurrent hyperammonemia were not specified in the article. i Asymptomatic adults diagnosed through cascade family testing. j Patient has a concurrent diagnosis of MCAD deficiency. Summary of CA‐VA cases reported in the literature: Additional MDEs, long‐term follow‐up, neurological outcome and long‐term management. On breast feeding, no protein restriction Sick‐day plan Minor LD (no formal testing) Normal growth and good developmental progress LD Speech delay Started on protein restriction after her first MDE. Later on, protein intake was liberalized outside MDEs. Sick‐day plan with protein restriction during illness Normal growth and development Biochemical profile normalized outside MDE Brain MRI: laminar subdural hematomas in the parietooccipital regions, posterior fossa, and posterior falx. Nonspecific hyperintensities in the deep WM in frontal, parietal and occipital lobes Regular mixed diet Sick‐day plan Discharged home on carnitine supplements (discontinued at the age of 3 months). Riboflavin (100–150 mg/day, discontinued at 3.6 years) No long‐term medications since the age of 3.6 years Normal growth and development Biochemical profile normalized outside MDE Brain MRI 4 DOL: normal Regular mixed diet Sick‐day plan Regular mixed diet Sick‐day plan Normal growth and development Biochemical profile normalized outside MDE Regular mixed diet Sick‐day plan Normal growth and development Normal biochemical investigations during febrile illnesses Low protein diet Sick‐day management (high calorie, lipid‐rich formula) Normal growth and development Normal neurological examination Continued to have elevated ammonia and lactate outside MDEs Sodium benzoate Carnitine Riboflavin Zinc Not reported. Brain MRI (MDE2): bilateral cerebral cortical cytotoxic edema Protein restriction (0.9–1 g/kg/day) Sick‐day plan Glycerol phenylbutyrate Sodium benzoate Normal growth and development Normal ammonia, PAA and UOA EEG: multi‐regional epileptiform discharges At 7 months: abnormal movements, EEG suggestive of bilateral generalized epileptiform activity. At 8 months: infantile spasm & developmental delay Microcephaly, hypotonia Brain MRI: mild cortical atrophy EEG: modified hypsarrhythmia during sleep At 9 months: developmental delay, normal ammonia and lactate Normal development Normal biochemical profile Normal brain MRI Sodium benzoate Carnitine GDD Microcephaly FTT Normal ammonia outside MDE Severe GDD Microcephaly FTT Mild ammonia and lactate elevation outside MDE GDD FTT Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal HC FTT Normal ammonia outside MDE Mild LD Normal growth Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal HC FTT Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE GDD Microcephaly FTT Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal HC FTT Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE Normal neurodevelopment Normal growth Normal HC Normal ammonia outside MDE GDD Failure to thrive Normal HC Normal ammonia outside MDE GDD Normal growth Normal HC Normal ammonia outside MDE Ongoing neurological abnormalities: central and peripheral hypotonia, poor suck. Brain MRI was not repeated after initial MDE Carglumic acid Biotin Riboflavin CoQ10 Normal development and growth Repeat PAA & UOA normalized Axial hypotonia. GDD Normal growth Brain MRI: Marked thinning of corpus callosum. Mild periventricular leukomalacia Microcephaly (at 3rd centile). Continued to have significant speech delay, mild to moderate intellectual disability Motor skills improved Brain MRI: minor abnormalities Mild speech delay Normal growth and physical examination Normal neurodevelopmental outcome Brain MRI (at 3 weeks): complete resolution of abnormalities found on initial MDE LD Microcephaly Normal neurodevelopmental outcome Brain MRI (11 months after initial MDE): mild residual gliotic changes in bilateral centrum semiovale and corona radiata, resolution of previously noted abnormalities Severe GDD Axial hypotonia Central hypertonia Microcephaly Stereotypic behavior and autistic features GDD Microcephaly Brain MRI (14 months after initial MDE): extensive residual gliotic changes in the bilateral periorlandic and insular cortices, subcortical WM, putamina, globi pallidi, and superior peduncles, new involvement of bilateral caudet heads and left thalamus GDD Hypotonia Recurrent symptomatic hypoglycemia Abbreviations: DOA, day of admission; DOL, day of life; FTT, failure to thrive; GDD, global developmental delay; HC, head circumference; LD, learning difficulties; MDEs, metabolic decompensation episodes; WM, white matter. Patient continued to have infrequent episodes of vomiting and ketoacidosis without hyperammonemia or elevated lactate. Second MDE were milder than the initial MDE. Patient was found to have elevated ammonia at 174 μmol/L on routine assessment at 1 month of age. No clinical symptoms were reported. Patient also reported in Ibrahim et al. [9] at 2 years of age. Patient was found to have elevated ammonia up to 340 μmol/L in routine assessment. In 2 episodes, the patient required PICU admission and was on hemofiltration for ammonia detoxification. In episode 2, he had increased intracranial pressure and cerebral edema. Patient presented with symptoms not usually seen in MDEs. No further details were provided in the report. Patients with recurrent hyperammonemia were not specified in the article. Asymptomatic adults diagnosed through cascade family testing. Patient has a concurrent diagnosis of MCAD deficiency. Clinical Presentation The hallmark of CA‐VA deficiency is an acute MDE characterized by hyperammonemic encephalopathy (86.5%), hyperlactatemia (79.7%), elevated ketones (49.3%), and mixed acid–base disturbances (Table 2) [3, 4, 13, 18, 20, 28]. Hypoglycemia was inconsistent across reported cases, occurring in only 37.7% of cases, and was not correlated with the severity of MDEs [3, 4, 5, 6, 7, 8, 10, 13, 15, 16, 18, 20, 22, 23]. Atypical presentations included hypoammonemia (n = 1) [21], normal lactate (n = 8) [18, 25], hyperglycemia (n = 1) [11], and cases without MDEs (n = 8) [25]. Case 1 exhibited recurrent hyperCKemia during MDEs, a finding observed in ten other cases, suggesting a possible underrecognized feature of CA‐VA deficiency [18, 23]. However, concurrent myositis in the context of febrile illnesses cannot be excluded. Therefore, routine assessment of CK and urine myoglobin levels in patients with CA‐VA deficiency is warranted. Liver transaminases were normal in our cases, consistent with most published reports (n = 8/13) [3, 11, 14, 27, 28]. Transaminitis was reported in five cases, one of which had accompanying hepatomegaly [6, 15, 17, 19, 24]. Biochemical Profile PAA showed elevated glutamine (59.4%) with low‐normal citrulline, consistent with secondary CPS1 deficiency, although arginine and ornithine levels varied among patients (Table 2) [4, 7, 10, 13]. The elevation in alanine (53.1%) and proline (28.1%) is consistent with the lactate level, reflecting mitochondrial dysfunction [3, 4, 6, 8, 13, 15, 22, 23, 28]. Analysis of UOA typically reveals marked ketonuria (84.4%) and lactic aciduria (81.3%), and in some cases, metabolites suggestive of multiple carboxylase (31%) or pyruvate carboxylase deficiency (34.4%) may be present [3, 28], while in other cases, the UOA profile remained normal (n = 9) [16, 18]. Urine orotic acid was either normal (n = 21) [3, 4, 8, 13, 14, 19, 26], similar to our cases, or mildly elevated (n = 1) [8], suggesting reduced carbamoyl phosphate production in CA‐VA deficiency, as opposed to primary urea cycle defects. Newborn screening could theoretically identify individuals with CA‐VA deficiency through elevated C3 and C5‐OH levels, as seen in multiple carboxylase defects [3, 8, 28]. However, both newborn screening and serial acylcarnitine levels were normal in our cases, even during acute MDEs (case 1 MDE2: C3:0.67 μmol/L (0.56–3.22), C5‐OH: 0.17 μmol/L (0.07–0.56), case 2 MDE1: C3:0.41 μmol/L (0.06–0.94), C5‐OH:0.06 μmol/L (0.02–0.08)), consistent with all previously reported cases (n = 11) [10, 13, 18, 22, 23, 24]. Moreover, 58% of cases present between the second and fourth days of life, often before newborn screening results are available [8, 28]. Neurological Manifestations and Neuroimaging Seizures and epileptic encephalopathy have been documented in cases with CA‐VA deficiency during MDE (n = 9/67), mostly provoked by hyperammonemic crises (Table 2) [6, 15, 16, 17, 26]. Although some cases demonstrate complete recovery (n = 3) [15, 17], chronic epilepsy (n = 2) [16, 18] and fatal refractory seizures (n = 1) [5] have been reported. EEG data remain among the most sparsely reported variables in the literature, documented only in four cases. Diffuse cerebral dysfunction was the predominant EEG finding in 2/4 cases, of which one case had electrographic seizures without overt clinical manifestations, raising the importance of EEG monitoring during MDEs [6, 15]. Although both clinical and electrical abnormalities are expected to improve with ammonia normalization, persistent multiregional epileptiform discharges have been reported (n = 1), indicating post‐MDE cortical hyperexcitability related to prolonged hyperammonemic injury [15]. Hypsarrhythmia consistent with West syndrome (n = 1) has also been documented [16]. In contrast, the EEG obtained during the initial MDE in case 1 was unremarkable. Normal neuroimaging was observed in six cases, of which three had single neonatal‐onset MDE (brain MRI, n = 3) [8, 12, 17] and three had recurrent neonatal‐onset MDE (computed tomography [CT], n = 3, Table 2) [18]. All cases with normal neuroimaging had normal neurological outcomes, except for one case with mild learning difficulties. Abnormal brain MRI was evident in 21 cases and fell along a severity spectrum. On the milder end, some patients displayed images consistent with hyperammonemic encephalopathy with selective involvement of the cerebral cortex and the subcortical white matter, reflecting a recoverable injury (n = 9) [14, 18, 26]. More severe cases demonstrated T2 signal hyperintensities and diffusion restriction extending to the thalami, basal ganglia, and brainstem, consistent with acute infarcts and indicating more extensive, potentially irreversible damage (n = 8) [6, 18, 26]. Baertling et al. [5] fatal case represents the most severe end of the spectrum, with neuroimaging showing severe brain herniation with increased intracranial pressure, indicating the progression of brain edema despite the normalization of ammonia and lactate levels. Fragoso et al. [26] formalized this spectrum into two radiological patterns, with the favorable outcome group (FOG) defined by selective involvement of the cortical and subcortical regions of the insular/peri‐insular, Sylvian/peri‐Sylvian, and peri‐Rolandic cortex. In contrast, the unfavorable outcome group (UOG) was characterized by more extensive lesions in these areas, as well as deep gray matter and brainstem involvement. These changes may result from a combination of factors, including hyperammonemia, hypoglycemia, carboxylase deficiency, and organic acid accumulation, causing cellular energy failure, reduced Na+/K+ ATPase activity, and ultimately cytotoxic cell edema [29]. While some cases demonstrated complete radiological resolution [26], chronic brain MRI changes have been reported, including cortical atrophy (n = 1) [16] and thinning of the corpus callosum and periventricular leukomalacia (n = 1; Table 3) [25]. Brain MRI in case 1 remained unremarkable throughout MDEs. In case 2, the initial brain MRI revealed nonspecific white matter injury that fully resolved on repeat imaging at 11 years of age, consistent with the FOG. Brain MRS has been reported in 6 cases, with normal results in one, similar to our two cases (Table 2) [26]. Elevated lactate (n = 1) [5], elevated glutamine and lactate (n = 1) [10], elevated glutamine/glutamate (n = 2) [26], and choline peak (n = 1) [19] have been reported, reflecting anaerobic metabolism defect, excitotoxicity and increased membrane turnover [30]. Metabolic Decompensation Episodes (MDEs) The majority of cases (44/67) experienced a single MDE, after which they remained metabolically stable with a normal biochemical profile, even during subsequent febrile illnesses (Table 3) [4, 6, 8, 10, 11, 12, 13, 15, 20, 22, 23, 27]. Clinical stability in these cases may be attributed to the progressive compensatory upregulation of CA‐VB activity [2]. A further six cases experienced a total of two MDEs before achieving similar metabolic stability [3, 4, 26]. At the severe end of the spectrum, 13.3% of cases had recurrent MDEs triggered by catabolic stress, most notably the seven cases reported by Al‐Thihli et al. [18] and the case reported by Stockdale et al. [14], who experienced seven episodes, the highest documented MDE count. Three fatalities were reported despite proper management, all occurring before the age of 2 years: in the neonatal period (n = 1) [21], at 18 months (n = 1) [5], and at 22 months (n = 1) [6]. Although most cases showed a decrease in the severity of MDEs with age [3, 4], one case continued to experience severe MDEs requiring admission to PICU [14]. The age at the last MDE varied across the reported cases. Most cases had their last MDE during the neonatal (n = 28/67) and infantile (n = 8/67) periods [3, 4, 6, 7, 8, 10, 12, 13, 15, 16, 17, 19, 20, 22, 23, 24, 26]. However, MDEs have been reported as late as 4 years 1 month, 5 years 9 months, and 6 years, confirming that the recurrence risk extends into childhood despite periods of clinical stability [4, 14, 26]. Case 2 had a single neonatal MDE and remained metabolically stable thereafter, consistent with most reported cases. In contrast, case 1 experienced four MDEs, the last occurring at the age of 8 years, extending the upper age limit for MDE recurrence beyond any previously reported case. This phenotypic discordance between two siblings sharing an identical biallelic variant in CA5A gene is not novel. Al‐Thihli et al. [18] documented substantial intrafamilial variability among 18 cases with the same founder mutation c.59G>A (Table 3). Interfamilial variability is equally striking; for instance, cases with the variant c.721G>A have been reported across different ethnic backgrounds and displayed markedly different clinical courses, with no consistent genotype–phenotype correlation. Several hypotheses may explain the phenotypic heterogeneity between cases 1 and 2. Gene modifiers acting independently of CA5A gene may influence the threshold for metabolic decompensation [18]. Additionally, environmental factors, including the frequency, severity, and pathogen burden of intercurrent illnesses in childhood, may determine how often the catabolic threshold is breached. Sex‐related differences in hepatic enzyme expression may influence the developmental upregulation of CA‐VB in the context of CA‐VA deficiency, leading to a higher compensatory plateau in males and earlier protection against MDE [31, 32, 33]. Impact on Neurodevelopment and Growth Normal developmental outcomes were reported in 67.2% (n = 45/67) of cases, the majority of whom (n = 33/45) experienced no further MDEs beyond their initial presentation (Table 3) [3, 4, 6, 7, 8, 10, 11, 12, 13, 15, 17, 18, 20, 22, 23, 24]. The remaining cases with normal outcomes had two or more MDEs (n = 7) [4, 18]. Approximately 25% (n = 18) of the cases exhibited a spectrum of neurodevelopmental abnormalities. Mild intellectual disability (ID, n = 4) and mild to moderate global developmental delay (GDD, n = 6) were the most frequently reported adverse outcomes among symptomatic cases [3, 4, 18, 25]. Notably, three cases presented with isolated speech delay or speech delay with ID in the absence of MDEs, representing a distinct phenotypic subgroup with MDE‐independent neurological injury [25]. Severe GDD was documented in six cases, several of whom exhibited abnormal neuroimaging and neurological abnormalities, suggesting a more devastating outcome [18, 26]. The neurodevelopmental outcome did not correlate with the genotype, number of MDEs, age of onset, age at last MDE, duration, or severity of hyperammonemia, consistent with significant intra‐ and interfamilial variability as described earlier [16, 18, 26]. The impact on the outcome may be attributed, in part, to differences in the severity of individual MDE‐related brain injuries [18, 26]. The impact of CA‐VA deficiency on somatic growth and head circumference is underappreciated (Table 3). Microcephaly was documented in eight cases [16, 18, 25, 26]. The occurrence of severe microcephaly in the context of a single neonatal MDE raises the possibility of brain injury triggered by the acute hyperammonemia superimposed on underlying chronic bicarbonate deficiency affecting cerebral growth [18, 26]. However, microcephaly was documented in the absence of MDEs, suggesting mechanisms beyond hyperammonemia alone [25]. Although Al‐Thihli et al. [18] raised the possibility of an unidentified co‐inherited disorder as a possible etiology, the initial WES/WGS and WES reanalysis failed to identify additional clinically relevant variants in these cases, whereas comprehensive genetic testing was not performed in the remaining cases [16, 18, 25]. Normal somatic growth was documented in most cases (n = 45/67) [3, 4, 18], whereas failure to thrive (FTT) was encountered in eight cases [18]. Although the impact of recurrent MDE may collectively impair weight gain and linear growth, it is not sufficient to explain FTT in cases with a single MDE. Notably, most cases with FTT also have significant neurological sequelae, which may impact feeding and later contribute to calorie deficits. Furthermore, chronic impairment of pyruvate carboxylase and gluconeogenesis may affect the availability of substrates for anabolic processes. In contrast, excessive growth has been reported in one case of obesity, which may reflect the impact of the high‐fat sick‐day formula used during intercurrent illnesses [6]. Case 1 demonstrated early fatigue‐related performance variability, along with reduced upper‐ and lower‐limb strength, suggesting decreased muscle energy production. Similarly, Case 2 showed signs of increasing fatigability and distractibility during neurodevelopmental assessment in early childhood, raising the possibility of a mild attention deficit. Both cases demonstrated normal growth, intellectual function, and neurological outcomes, with improvements over time in physical and cognitive abilities, consistent with the generally favorable prognosis seen in well‐managed cases. Additionally, our cases continued to have normal ophthalmology, cardiac, hepatic, and renal assessments, consistent with most reported cases. This finding distinguishes CA‐VA deficiency from primary mitochondrial disorders, in which multi‐organ involvement is typical [34]. Acute and Long‐Term Management Owing to the rare and novel nature of CA‐VA deficiency, no clinical management guidelines have yet been published. However, there is a broad consensus on the approach to acute MDEs (Table 2), which focuses on the reversal of catabolism and anabolism induction by providing high caloric intake using IV dextrose (10% at 150% maintenance) and age‐appropriate doses of IV lipids (1–2 g/kg/day), avoidance of fasting to suppress endogenous protein catabolism, and temporary protein restriction for 24–48 h with gradual introduction of essential amino acids as ammonia levels normalize [3, 28, 35]. Bicarbonate supplementation has been used as a symptomatic treatment (n = 9) to correct the metabolic acidosis accompanying MDEs, often prior to diagnostic confirmation [6, 7, 8, 15, 17, 21, 24]. Carglumic acid (100 mg/kg/day) provides the most targeted acute intervention [3, 4, 18, 24]. When used (n = 27), it significantly shortened the duration of hyperammonemia compared to standard measures alone [8, 14]. Further, it was employed proactively in three cases identified antenatally [9, 24]. While a single dose of carglumic acid has been successfully used in some cases (n = 2), a 3‐ to 5‐day course may be required when hyperammonemia persists, in combination with adjunct therapies and close ammonia monitoring [3, 14]. Ammonia scavengers (sodium benzoate and sodium phenylacetate), sometimes combined with l‐arginine, were used as adjunct therapies, with or without extracorporeal ammonia removal, in cases with severe, refractory hyperammonemia with progressive encephalopathy (n = 32) [3, 4, 18]. Mitochondrial cofactor supplementation was administered during acute MDEs in 13 cases, with variable agent selection, including l‐carnitine (n = 13), biotin (n = 6), CoQ 10 (n = 3), riboflavin (n = 3), vitamin C (n = 2), cobalamin (n = 2), thiamine (n = 1), folic acid (n = 1), and zinc (n = 1), reflecting the original diagnostic uncertainty given the overlap with primary mitochondrial disorders. In the absence of biochemical evidence of primary mitochondrial dysfunction, there is no established rationale to continue these agents once the diagnosis of CA‐VA deficiency is confirmed and metabolic stability is achieved. Long‐term pharmacological intervention is not routinely required in most patients outside acute MDEs (Table 3) [3, 4, 6, 7, 8, 10, 11, 13, 19, 24]. Long‐term ammonia scavengers (n = 6) and protein restriction (n = 5) were used in a minority of cases, some of which had baseline persistent hyperammonemia or recurrent MDEs [3, 6, 12, 14, 17, 20]. Outside MDEs, long‐term administration of carglumic acid was not recommended and was used exclusively during intercurrent illnesses (n = 2), reflecting the episodic nature of hyperammonaemia in CA‐VA deficiency [3, 7]. All patients should be provided with a personalized sick‐day protocol during periods of febrile illness and catabolic states, consisting of high‐calorie intake from fats and carbohydrates, temporary protein restriction, strict avoidance of fasting, and clear criteria for hospital admission [28]. Although long‐term outcomes are generally favorable in well‐managed cases, ongoing surveillance is recommended given the risk of MDE recurrence into later childhood and potential neurodevelopmental sequelae. Conclusion CA‐VA deficiency is a rare yet clinically significant inherited metabolic disorder that presents with hyperammonemic encephalopathy, lactic acidosis, and ketosis, mostly in neonates and infants, while some patients may present later in life or remain asymptomatic until adulthood. There is noticeable clinical and biochemical heterogeneity, intrafamilial and interfamilial variability, and no clear genotype–phenotype correlation. Outcomes vary among affected individuals. While the prognosis is mostly favorable in promptly treated patients, severe and fatal outcomes have been reported. The lack of consistent biochemical or radiological signatures underscores the importance of molecular testing for the early diagnosis of CA‐VA deficiency. Consensus guidelines for the treatment and long‐term monitoring of CA‐VA deficiency are essential. Author Contributions S.S. contributed to the design and concept, data collection, data analysis and interpretation, literature review, manuscript drafting, revision and editing, figures and tables preparation, and manuscript final approval and submission. A.M. contributed to the manuscript design, data analysis and interpretation, literature review, manuscript drafting, revision and editing, and supplemental data preparation. G.H. and S.S.‐I. provided clinical care and contributed to the manuscript review and final approval. C.K. provided clinical care and contributed to the design, concept, data analysis, and interpretation. R.S.‐Z. provided ongoing clinical care and contributed to the design and concept, data collection, data analysis and interpretation, manuscript revision and editing, and final review of the manuscript for submission. Funding The authors have nothing to report. Ethics Statement All procedures and investigations in this article were part of the routine standard of care and did not require ethical approval. Consent Written informed consent and assent were obtained from all participants for inclusion in the study. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors would like to thank the patients and their families for consenting to the publication of this case report. The authors extend their appreciation and gratitude to all clinical and laboratory medical staff for their significant contributions to patient care. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.